Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast CancerFebruary 3rd 2023
Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.
Pembrolizumab/Chemo Improves Survival Vs Chemo Alone in Biliary Tract CancerFebruary 2nd 2023
Data from the final analysis of the phase 3 KEYNOTE-966 trial indicate that pembrolizumab plus chemotherapy yields improvements in overall survival compared with chemotherapy alone in patients with advanced biliary tract cancer.
FDA Grants Orphan Drug Exclusivity to Sodium Thiosulfate Injection for Pediatric CancerFebruary 1st 2023
The FDA gives orphan drug exclusivity to sodium phosphate injection for the prevention of cisplatin-related hearing loss in pediatric patients 1 month and older with localized, non-metastatic solid tumors.
FDA Accepts IND Application for DK210 in EGFR Overexpressing Solid TumorsJanuary 31st 2023
Investigators will evaluate DK210 in a first-in-human phase 1 clinical trial following the FDA’s review of an investigational new drug application for the compound for locally advanced or metastatic EGFR-positive solid tumors.
Adjuvant Chemo After Neoadjuvant Chemo/Surgery Linked With Survival in PDACJanuary 27th 2023
Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.
‘Multipronged’ Plan May Allay Opioid Disparities for People of Color With CancerJanuary 26th 2023
Black and Hispanic patients are less likely to receive opioids than their White counterparts; bias training and logistical support may act as potential strategies to mitigate these disparities, according to an expert from Dana-Farber Cancer Institute.
FDA Accepts Supplemental NDA for Avapritinib in Indolent Systemic MastocytosisJanuary 24th 2023
Data from the phase 2 PIONEER trial supports the supplemental new drug application for avapritinib in adult patients with indolent systemic mastocytosis, an uncontrolled proliferation and activation of mast cells.
Veliparib/Cisplatin May Improve Survival Vs Placebo in BRCA-Like Metastatic TNBCJanuary 19th 2023
Cisplatin plus veliparib appears to improve progression-free survival among patients with BRCA-like metastatic triple-negative breast cancer, but not in those with non–BRCA-like metastatic breast cancer.